Photo: Shutterstock
Having reached over 6 million U.S. COVID-19 cases and nearly 200,000 U.S. deaths, with in-person learning either scuttled or off to a rough start, and with the U.S. economy reeling from layoffs, furloughs, and an economic shutdown, the country’s best hope of returning to normal is the development of a safe and effective COVID-19 vaccine. In record time, several vaccine candidates have emerged—among them Moderna’s lipid nanoparticle mRNA vaccine. Early clinical results for Moderna’s vaccine are promising, and in anticipation of FDA approval, the U.S. government recently pre-purchased 100 million doses. However, significant patent issues are brewing in the background, underlying the risks and rewards of Moderna’s vaccine.
Infringment on Other Patents
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
